Amgen Commits to Affordable Healthcare with Innovative Pricing and U.S. Manufacturing Investments

Amgen Reinforces Commitment to Affordable Healthcare through Innovative Pricing Strategies

Amgen, a leading biotechnology company based in Thousand Oaks, California, is taking significant steps to enhance the affordability of medications for American patients. In a move that aligns with ongoing national discussions about healthcare costs, Amgen expands its direct-to-patient program, AmgenNow™, to include its products Aimovig® and Amjevita®, both offered at drastically reduced prices of $299 per month. This pricing represents nearly 60% and 80% discounts from their respective list prices, making crucial medication more accessible to patients. This expansion follows the successful launch of AmgenNow in October 2025, which had already made Repatha® available for $239 monthly—a similar 60% discount. Importantly, this initiative is designed to reach all eligible patients, including those who are uninsured or on high-deductible plans, underscoring Amgen's commitment to supporting vulnerable populations in the U.S. healthcare system.

Amgen's broader strategy for reducing medicine costs is part of a larger investment in U.S. manufacturing and research, reflecting over $40 billion committed since 2018. The company announces a new capital investment of $2.5 billion dedicated to U.S. manufacturing, with substantial allocations to states like Ohio and North Carolina. These investments not only bolster Amgen's production capabilities but also contribute to job creation and economic growth in the regions they serve. The favorable tax policies, such as those included in the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025, further enhance Amgen's ability to innovate and manufacture new therapies domestically. By focusing on localized production and R&D, Amgen positions itself as a key player in the ongoing dialogue about healthcare affordability and accessibility in the U.S.

Recognized as one of the "World's Most Innovative Companies" by Fast Company in 2024, Amgen leverages cutting-edge technology and genetic research to advance treatments for complex diseases, including cancer and heart disease. The company’s commitment to innovation extends beyond its products to its operational strategies, which are increasingly geared toward making treatments more affordable. As Amgen continues to refine and expand its offerings, it plays a crucial role in reshaping the landscape of drug pricing. By prioritizing patient access and affordability, Amgen not only enhances its reputation but also contributes significantly to the overall objective of improving healthcare outcomes in America.

In related developments, President Donald Trump recently announced agreements with nine major pharmaceutical companies—including Amgen—aimed at reducing prescription drug costs for Americans. This initiative represents a broader commitment to align U.S. drug prices with those in other affluent nations, especially benefitting low-income individuals reliant on Medicaid. The administration's efforts reflect ongoing concerns about high healthcare costs and aim to alleviate financial burdens for families across the country. Additionally, a forthcoming website, TrumpRX.gov, is set to launch in January 2026 to provide Americans with better access to lower drug prices, further reinforcing the collaborative approach between the government and the pharmaceutical industry in addressing this critical public health issue.